AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
19 nov. 2024 08h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer...
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
15 nov. 2024 07h29 HE
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with...
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
06 nov. 2024 09h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss...
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
09 oct. 2024 09h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that Tom Equels, Chief Executive Officer of AIM, will participate in...
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
03 oct. 2024 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has...
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
30 sept. 2024 09h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 30, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a...
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
27 sept. 2024 08h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM will...
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
19 sept. 2024 08h00 HE
|
AIM ImmunoTech Inc.
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no...
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
11 sept. 2024 09h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that an analysis of the complete clinical patient data from the AMP-518 clinical...
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
20 août 2024 08h30 HE
|
AIM ImmunoTech Inc.
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential of Ampligen and...